The trajectory of Sildenafil presents a intricate picture for shareholders. While the initial release generated substantial gains, the end of its patent opened the floodgates to generic versions, dramatically diminishing sales. This creates a specific challenge for firms depending on comparable blockbuster products, suggesting that a blind particip

The legacy of Viagra, and its parent company copyright, presents a challenging case study for investors. At first a blockbuster drug, generating billions in sales , its patent expiration created a deluge of generic competition , significantly impacting its market share . While some businesses may try to capitalize on related treatments , the presen